Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 310895. Отображено 100.
05-01-2012 дата публикации

Pharmaceutical compositions of dextran polymer derivatives

Номер: US20120003282A1
Автор: Corey J. Bloom, Daniel E. Dobry, Daniel T. Smithey, David K. Lyon, David T. Vodak, Dwayne T. Friesen, Michael M. Morgen, Warren K. Miller
Принадлежит: Bend Research Inc

Pharmaceutical compositions are provided comprising an active agent and a dextran polymer derivative. The compositions include from 0.01 to 99 wt % of an active agent and from 1 to 99.99 wt % of a dextran polymer derivative. The dextran polymer derivative is selected from dextran acetate, dextran propionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran propionate succinate, dextran acetate propionate succinate, and mixtures thereof.

Подробнее
Номер записи: 1
05-01-2012 дата публикации

Anti-inflammatory dissolvable film

Номер: US20120003292A1
Автор: Aron J. Saffer, William Zev Levine, Zvi G. Loewy
Принадлежит: Individual

Provided, among other things, is a slowly dissolvable film comprising: herbal bioactive agent(s); and polymer(s), dissolvable in the aggregate, wherein the film becomes adhesive as it is placed against a mucosal surface and begins to absorb moisture therefrom.

Подробнее
Номер записи: 2
05-01-2012 дата публикации

Solid Dosage Forms Of Bendamustine

Номер: US20120003309A1
Автор: Jeffrey Colledge, Margaretha Olthoff, Taoufik Ouatas, Thomas Alfred Profitlich, Ulrich Patzak
Принадлежит: ASTELLAS DEUTSCHLAND GMBH

In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable for oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.

Подробнее
Номер записи: 3
05-01-2012 дата публикации

Dpp iv inhibitor formulations

Номер: US20120003313A1
Автор: Anja Kohlrausch, Gerd Seiffert, Patrick Romer
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

Подробнее
Номер записи: 4
05-01-2012 дата публикации

Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Номер: US20120003318A1
Автор: Carlos A. Schuler, Rangachari Narasimhan
Принадлежит: Incarda Therapeutics Inc

Methods of treating atrial arrhythmia include administering an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof, such that the at least one antiarrhythmic pharmaceutical agent first enters the heart through the pulmonary vein to the left atrium. Other methods of treating atrial arrhythmia include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. An amount of the at least one antiarrhythmic pharmaceutical agent may peak in the coronary sinus of the heart at a time ranging from 10 seconds to 30 minutes from initiation of the administering. Unit doses, aerosols, and kits are also contemplated.

Подробнее
Номер записи: 5
12-01-2012 дата публикации

"Methods of Reducing Nephrotoxicity in Subjects Administered Nucleoside Phosphonates"

Номер: US20120010170A1
Автор: George R. Painter
Принадлежит: Individual

A conjugate compound comprising an acyclic nucleoside phosphonate covalently coupled to a lipid for the therapeutic and/or prophylactic treatment of viral infection in an immunodeficient subject is described, along with compositions and methods of using the same. A preferred conugate compound is CMX001, having formula (I) or a pharmaceutically acceptable salt thereof.

Подробнее
Номер записи: 6
12-01-2012 дата публикации

Nucleotide Analogue Prodrug and the Preparation Thereof

Номер: US20120010171A1
Автор: Jiandong Yuan
Принадлежит: Brightgene Bio Medical Technology Co Ltd, Jiangsu Chia Tai Tianqing Pharmaceutical Co Ltd

The present invention provides: 1) Derivative solid form of 9-[2-(R)-[bis[pivaloyloxymethoxy]-phosphinylmethoxy]propyl]adenine (bis-POM PMPA, abbreviated as TD hereinafter), including crystalline form A and form B of TD, TD fumarate salts and cyclodextrin inclusion complex of TD; 2) Synthesis and purification methods of TD and Solidification method of TD oil, including converting TD oil to crystalline TD in Form A and Form B, solid TD salts and cyclodextrin inclusion complex of TD; 3) Stable pharmaceutical compositions containing TD derivatives and their preparation; 4) The use of the above TD derivatives in the antiviral treatments, especially in the treatment of HIV, HBV, CMV, HSV-1, HSV-2 and human Herpes virus infections.

Подробнее
Номер записи: 7
12-01-2012 дата публикации

Non-sedating antihistamine injection formulations and methods of use thereof

Номер: US20120010217A1
Автор: Jie Du
Принадлежит: Individual

Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute urticaria or angioedema associated with an acute allergic reaction are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms with the same number of mg of cetirizine.

Подробнее
Номер записи: 8
12-01-2012 дата публикации

Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids

Номер: US20120010280A1
Автор: Danilo Aleo, Maria Grazia Antonietta Saita, Maurizio Rolando, Sergio Mangiafico, Stefano Barabino
Принадлежит: TRB CHEMEDICA INTERNATIONAL SA

The invention concerns topical compositions for the prevention and treatment of ocular pathologies, in particular inflammatory keratites and conjunctivites and dry eye syndrome, containing as active ingredients polyunsaturated fatty acids of the types omega-3 and omega-6, and specifically EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid) and GLA (γ-linolenic acid), mixed with vitamin E acetate and formulated in a stable composition in hydrogel, i.e. in dispersed form in an aqueous vehicle containing one or more gelling polymers. The proposed compositions are particularly indicated for use as artificial tears.

Подробнее
Номер записи: 9
12-01-2012 дата публикации

System for controlling means for injection of anaesthetics or sedatives with a view to inducing anaesthesia or sedation

Номер: US20120010591A1
Автор: Bernard Trillat, Ngai Lui, Thierry Chazot
Принадлежит: HOPITAL FOCH

This system is characterized in that it includes means ( 2 ) for acquiring a signal representative of the electrocortical activity of the patient ( 1 ), means ( 3 ) for analyzing this signal in order to extract therefrom an anesthetic depth signal, means ( 4, 5, 6 ) for tracking the value and the time-dependent evolution of this anesthetic depth signal, associated with means ( 4, 5, 6 ) for computing control signals for controlling the injection means, in order to automatically bring the anesthetic depth signal to below a predetermined value during at least one predetermined period of time, in that the means for injecting anesthesia agents comprise first means ( 7 ) for injecting a hypnotic agent, and second means ( 8 ) for injecting a morphinomimetic agent, in that the means for computing control signals for controlling the injection means comprise means for inputting by an operator a type of anesthesia induction selected from a set of induction types which differ by the initial concentration of hypnotic agent and in that the means for inputting the induction type comprise means for determining the initial concentration of hypnotic agent, with which is associated an predetermined initial concentration of morphinomimetic agent depending on the selected induction type.

Подробнее
Номер записи: 10
19-01-2012 дата публикации

High-throughput production of ingestible event markers

Номер: US20120011699A1
Автор: Benedict J. Costello, Eric Snyder, Gregory Moon, Hooman Hafezi, Kityee Au-Yeung, Maria Casillas Holen, Mark Zdeblick, Mauro Folena, Pratish Rao, Robert Duck, Timothy Robertson
Принадлежит: Proteus Biomedical Inc

High-throughput ingestible event marker manufacturing systems are provided. The systems include an assembly unit configured to stably associate an ingestible event marker with a carrier to produce a product. Also provided are manufacturing methods to produce such products which include assembling an ingestible event marker with an assembly unit configured to stably associate an ingestible event marker with a carrier.

Подробнее
Номер записи: 11
19-01-2012 дата публикации

Methods and compositions for cns delivery of heparan n-sulfatase

Номер: US20120014936A1
Автор: Brian Vernaglia, Farah Natoli, Gaozhong Zhu, Jamie Tsung, Jennifer Terew, Jing Pan, Pericles Calias, Richard Pfeifer, YUAN Jiang, Zahra Shahrokh
Принадлежит: Shire Human Genetics Therapies Inc

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.

Подробнее
Номер записи: 12
19-01-2012 дата публикации

Compositions with reduced dimer formation

Номер: US20120014978A1
Автор: Paul Laidler, Roderick Peter Hafner
Принадлежит: Circassia Ltd

The present invention relates to the use of a non-reducing carbohydrate or carbohydrate derivative and at least one agent which inhibits dimer formation in a freeze-dried composition comprising at least one peptide that contains a free cysteine residue, to provide a freeze-dried composition with improved long-term storage stability.

Подробнее
Номер записи: 13
19-01-2012 дата публикации

Modified release formulations containing drug-ion exchange resin complexes

Номер: US20120015030A1
Автор: Ketan Mehta, Yu-Hsing Tu
Принадлежит: Tris Pharma Inc

A solid dose composition containing a mixture of a cured, modified release-barrier coated methylphenidate-ion exchange resin complex-matrix and an uncoated methylphenidate-ion exchange resin complex is described. The barrier coated methylphenidate-ion exchange resin complex-matrix comprises methylphenidate complexed with a pharmaceutically acceptable ion-exchange resin to form the complex which is admixed with a polymer to form a methylphenidate-ion exchange resin complex-matrix, which is subsequently coated with a modified release coating. The modified coating contains polyvinyl acetate polymer and a plasticizer and is cured.

Подробнее
Номер записи: 14
19-01-2012 дата публикации

Enterically coated cysteamine, cystamine and derivatives thereof

Номер: US20120015038A1
Автор: Jerry Schneider, Ranjan Dohil
Принадлежит: UNIVERSITY OF CALIFORNIA

The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

Подробнее
Номер записи: 15
19-01-2012 дата публикации

Traditional chinese medicinal ointment for treating burn, scald and infective trauma and preparative method thereof

Номер: US20120015041A1
Автор: Xinwei Sun
Принадлежит: Individual

This invention is disclosing a pure ointment of traditional Chinese medicine which was invented to treat burn or scald, and infectious trauma, and its preparation. The ointment has solved a number of problems in the treatment of burn or scald, and infectious trauma, such as the high cost of current drugs, post-treatment scar, and unfavorable therapeutic effect. The advantages of this ointment include low cost, favorable therapeutic effect, short course, and without scar after treatment. Its formula is based on the weight of every five hundred portions of following ingredients: lithospermum, 4-10 portions, beeswax, 5-20 potions, insect-white wax, 5-20 portions, and lard, 450-486 portions.

Подробнее
Номер записи: 16
19-01-2012 дата публикации

Formulations for the treatment of urushiol-induced contact dermatitis

Номер: US20120015044A1
Автор: Angela Hansen, Laszlo TREIBER
Принадлежит: Laszlos Solutions Inc

Disclosed herein are compositions comprising: a pharmaceutically acceptable oxidizing agent; a pharmaceutically acceptable base; and a pharmaceutically acceptable solvent or mixture of solvents. Also disclosed are methods of treating urushiol-induced contact dermatitis in a patient, the method comprising: identifying a patient in need thereof; and administering to the patient a composition as described herein. Further disclosed herein are devices for the treatment of urushiol-induced contact dermatitis, the device comprising: an absorbent material, contained therein a composition as described herein; and means for attaching the device to the skin of a patient in need thereof.

Подробнее
Номер записи: 17
19-01-2012 дата публикации

Pharmaceutical composition for external use

Номер: US20120015997A1
Автор: Akira Nozawa, Hirokazu Kobayashi, Hiroyuki Fujii, Toyohiko Miki
Принадлежит: Nihon Nohyaku Co Ltd, Pola Pharma Inc

Provided is a pharmaceutical composition for external use, including: (i) a compound represented by structural formula (2) and/or a salt thereof; and (ii) N-methyl-2-pyrrolidone.

Подробнее
Номер записи: 18
26-01-2012 дата публикации

Method of creating salt aerosol for breathing by nebulizing an aqueous saline solution

Номер: US20120018526A1
Автор: Constantin Tiba, Livia Tiba
Принадлежит: Individual

The present invention concerns a method for nebulizing an aqueous saline solution comprising sodium chloride, the method comprising the steps of: placing a quantity of the aqueous saline solution having a salt concentration ranging between 0.5 mg/mL and the NaCl solubility in water at 25° C. into a chamber of an ultrasonic nebulizer, the ultrasonic nebulizer having at least one ultrasonic cell used for nebulizing the saline solution; operating the ultrasonic nebulizer to generate droplets of the aqueous saline solution between 0.1 microns and 5 microns in size and in a quantity between 1 ml and 200 ml per hour; and forcing the nebulized saline solution droplets to leave the chamber through at least one opening of the ultrasonic nebulizer such as to place the nebulized saline solution droplets into the indoor air. The invention further concerns a method of treatment of respiratory ailments.

Подробнее
Номер записи: 19
26-01-2012 дата публикации

Use of Simple Amino Acids to Form Porous Particles

Номер: US20120020887A1
Автор: Michael M. Lipp, Ralph W. Niven, Richard P. Batycky
Принадлежит: Individual

Particles having a tap density of less than 0.4 g/cm 3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.

Подробнее
Номер записи: 20
26-01-2012 дата публикации

Thermosensitive hydrogel composition and method

Номер: US20120020932A1
Автор: Archit Sanghvi, Jian Q. Yao, Jizong Gao, Xiao Huang
Принадлежит: Zimmer Orthobiologics Inc

A hydrogel-forming composition is provided that comprises an extracellular matrix protein, hyaluronic acid, and a thermosensitive biocompatible polymer such as methylcellulose. The hydrogels can provide a therapeutic effect; further, the hydrogels may comprise an optional therapeutic agent such as cells or a pharmaceutical composition. The composition may be injected to an area in need of treatment by the therapeutic agent. The composition may form a gel at about 37° C., such that the gel maintains the therapeutic agent in the area of the body in need of such treatment.

Подробнее
Номер записи: 21
26-01-2012 дата публикации

Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects

Номер: US20120020951A1
Автор: Curtis Thompson, Gregory I. Frost, Harold Michael Shepard, Xiaoming Li
Принадлежит: Individual

Provided herein are methods for ameliorating an adverse effect of systemic administration of a PEG hyaluronan degrading enzyme to a subject. The methods involve systemically administering a PEGylated hyaluronan degrading enzyme, particularly a PEGylated hyaluronidase, such as any of the animal or bacterial hyaluronidases, to the subject and administering an amount of a corticosteroid sufficient to ameliorate the adverse effect. Also provided are method of treating a hyaluronan-associated disease or condition for single-agent therapy or combination therapy.

Подробнее
Номер записи: 22
26-01-2012 дата публикации

Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle

Номер: US20120022001A1
Автор: David F. Driscoll
Принадлежит: STABLE SOLUTIONS LLC

A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.

Подробнее
Номер записи: 23
26-01-2012 дата публикации

Composition and methods of treatment of bacterial meningitis

Номер: US20120022031A1
Автор: Robert B. Boyd
Принадлежит: NBR PATHFINDER LLC

A diluted solution of ceftiofur sodium is intrathecally or ventricularly delivered to effectively treat bacterial meningitis while maintaining the patient's threshold and reducing the likelihood of seizure.

Подробнее
Номер записи: 24
26-01-2012 дата публикации

Animal treatment formulation and methods of use

Номер: US20120022038A1
Автор: Fadil Al Alawi, Kiro Risto Petrovski, Wayne Frederick Leech
Принадлежит: Mastitis Res Centre Ltd

The present invention relates to a formulation for administration to the teat canal of the mammary gland of an animal, the formulation including: a physical barrier material, characterised in that the formulation includes sufficient antibiotic in relation to physical barrier material such that the formulation is configured to disintegrate over a period of time after administration to the teat canal.

Подробнее
Номер записи: 25
26-01-2012 дата публикации

Novel cyanopyrimidine derivative

Номер: US20120022077A1
Автор: Daisaku Michikami, Hiroyuki Yamazaki, Hisashi Shinohara, Keisuke Hino, Kuni Ito, Norifumi Sato, Yasuhiro Takeji, Yohei Yuki
Принадлежит: Otsuka Pharmaceutical Co Ltd

The present invention relates to a novel cyanopyrimidine compound and a pharmaceutical composition which have a safe and potent adenosine A2a receptor agonistic activity.

Подробнее
Номер записи: 26
02-02-2012 дата публикации

Transdermal pharmaceutical preparations

Номер: US20120024743A1
Автор: Endre Mikulásik, Patrik Fazekas
Принадлежит: EGIS PHARMACEUTICALS PLC

The present invention relates to semisolid transdermal pharmaceutical preparation having enhanced stability and bioavailability, wherein the particles are coated by a volatile silicon oil component and the thus obtained suspension is dispersed in a gel or cream base.

Подробнее
Номер записи: 27
02-02-2012 дата публикации

Spray-Dried Blood Products and Methods of Making Same

Номер: US20120027867A1
Автор: Joseph A. Dacorta, Michael Lawrence Galiger, Thomas H. Fischer
Принадлежит: Entegrion Inc

The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above.

Подробнее
Номер записи: 28
02-02-2012 дата публикации

Storage-stable aqueous ophthalmic formulations

Номер: US20120028910A1
Автор: Elisabeth Latour, Harun Takruri, Jean-Philippe Combal
Принадлежит: Fovea Pharmaceuticals SA

Storage-stable, topically ocularly administrable aqueous ophthalmic formulations containing at least one closporine are useful for treating and/or preventing ophthalmic diseases or disorders afflicting humans or animals, notably related to inflammatory conditions, more particularly administrable to the front of the eye and which provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision.

Подробнее
Номер записи: 29
02-02-2012 дата публикации

Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications

Номер: US20120028922A1
Автор: Fotini Sampalis
Принадлежит: Individual

A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.

Подробнее
Номер записи: 30
02-02-2012 дата публикации

Medicinal Cream Made Using Neomycin Sulphate, Betamethasone Valerate, And Chitosan, And A Process To Make The Same

Номер: US20120028942A1
Автор: Haridas Sankar, Kuppusamy Senthilkumar, Madhavan Srinivasan, Neelakandan Narayanan Chulliel, Vanangamudi Subramaniam Sulur
Принадлежит: Apex Labs Private Ltd

The present invention is directed to a composition for treating bacterial skin infections & skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, a corticosteroid and an antibacterial active ingredient. It discloses a composition for treating bacterial skin infections & skin inflammation, along with skin rejuvenation containing a) a biopolymer in the form of chitosan, b) a combination of active pharmaceutical ingredients (APIs), neomycin sulphate & betamethasone valerate used in treating bacterial skin infections & skin inflammations, c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants and d) water. The active ingredients, namely chitosan, a corticosteroid Betamethasone Valerate, and an antibacterial agent Neomycin Sulphate, are incorporated in cream base for use in treating bacterial skin infections and skin inflammation due to allergy & itching, & wounds on human skin involving contacting human skin with the above identified composition.

Подробнее
Номер записи: 31
02-02-2012 дата публикации

Clonidine for treatment of bone cancer

Номер: US20120029042A1
Автор: Vanja Margareta King
Принадлежит: WARSAW ORTHOPEDIC INC

The present invention is directed to a method for treating osteolytic bone cancer. The method comprises implanting a drug depot locally at or near the osteolytic bone cancer, wherein the drug depot comprises at least one biodegradable polymer and clonidine in an amount from about 0.1 wt. % to about 30 wt. % of the drug depot.

Подробнее
Номер записи: 32
02-02-2012 дата публикации

7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof

Номер: US20120029044A1
Автор: Gwenaella Rescourio, Jurg R. Pfister, Meenakshi S. Venkatraman, Xiaoming Zhang
Принадлежит: Theron Pharmaceuticals Inc

Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as pulmonary diseases, are provided.

Подробнее
Номер записи: 33
02-02-2012 дата публикации

Posterior segment drug delivery

Номер: US20120029470A1
Автор: Cary J. Reich, Douglas Sutton, Eugene de Juan, Jr., Hanson S. Gifford, Iii, K. Angela Macfarlane, Kathleen Cogan Farinas, Michael Barrett, Randolph E. Campbell, Yair Alster
Принадлежит: ForSight Vision4 Inc

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

Подробнее
Номер записи: 34
09-02-2012 дата публикации

Dry powder formulation comprising a phosphodiesterase inhibitor

Номер: US20120031403A1
Автор: Daniela Cocconi, Francesca Schiaretti, Roberto Bilzi
Принадлежит: Chiesi Farmaceutici SpA

Pharmaceutical formulations in the form of inhalable dry powder comprising particles of a phosphodiesterase-4 inhibitor as active ingredient are useful for the prevention and/or treatment of respiratory diseases, such as asthma and COPD.

Подробнее
Номер записи: 35
09-02-2012 дата публикации

Ophthalmic preparation containing menthyl ester of indomethacin

Номер: US20120034278A1
Автор: Joseph Schwarz, Michael Weisspapir
Принадлежит: Alpharx Inc

There is provided an ophthalmic pharmaceutical preparation comprising menthyl ester of indomethacin as an active ingredient. Also provided are different possible formulations of the ophthalmic preparation, and different methods of treating ophthalmic irritation using the ophthalmic preparation.

Подробнее
Номер записи: 36
09-02-2012 дата публикации

Combination of compounds for treating or preventing skin diseases

Номер: US20120035123A1
Автор: André Jomard, Laurent Fredon, Olivier Roye
Принадлежит: Galderma Research and Development SNC

A combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea is described. The combination of a compound of the avermectin family or of the mylbemycin family with a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists is also described. In addition, a product in the form of a kit including: (a) a first composition containing a compound of the avermectin family or of the mylbemycin family, and (b) a second composition different from the first one and containing a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists, as a combination product to be used as a drug for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay is described.

Подробнее
Номер записи: 37
09-02-2012 дата публикации

Ophthalmic compositions and methods for treating ophthalmic conditions

Номер: US20120035148A1
Автор: Scott M. Whitcup
Принадлежит: Allergan Inc

Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component.

Подробнее
Номер записи: 38
09-02-2012 дата публикации

Antiparasitic agent for fish and method of controlling proliferation of fish parasites

Номер: US20120035181A1
Автор: Fumi Kawano, Noritaka Hirazawa
Принадлежит: Nippon Suisan Kaisha Ltd

A method of controlling proliferation of fish parasites comprising the administration of 1 to 50 mg/kg fish body weight/day of an inhibitor of folate synthesis and/or an inhibitor of folate activation to fish continuously for 1 to 2 weeks. Using a combination preparation composed of an inhibitor of folate synthesis and an inhibitor of folate activation is preferable, and a sulfonamide is preferable for the inhibitor of folate synthesis. A dihydrofolate reductase inhibitor, a folate antagonist, etc., can be used as the inhibitor of folate activation. The antiparasitic agent is able to exterminate fish parasites via oral administration. It is particularly effective against parasites belonging to the ciliate group among fish parasites.

Подробнее
Номер записи: 39
09-02-2012 дата публикации

Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies

Номер: US20120035230A1
Автор: Alan D. Snow, F. Michael Hudson, Joel Cummings, Luke A. Esposito, Manfred Weigele, Thomas Lake
Принадлежит: ProteoTech Inc

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Подробнее
Номер записи: 40
16-02-2012 дата публикации

Chewing Gum And Particulate Material For Controlled Release Of Active Ingredients

Номер: US20120039981A1
Автор: Jette Baek Andersen, Kurt Moller Pedersen
Принадлежит: Fertin Pharma AS

A particulate material for controlled release of active ingredients includes a combination of one or more active ingredients, including nicotine, and an inorganic mineral filler, in which the active ingredient is reversibly absorbed into and/or adsorbed onto the inorganic mineral filler, and the BET specific surface area of the inorganic mineral filler is above 15 m 2 /g, the BET specific surface area measured in accordance with ISO 9277. Further, a chewing gum having the particulate material includes a combination of one or more active ingredients, such as nicotine or a flavoring agent, and an inorganic mineral filler. Finally, the method of producing the chewing gum is provided. The invention is particularly advantageous for controlled release of active ingredients.

Подробнее
Номер записи: 41
16-02-2012 дата публикации

Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish

Номер: US20120040010A1
Автор: Brian Carpenter, Moti Harel
Принадлежит: Individual

The invention relates to a composition and a method for manufacturing semi-dry or dry particles containing a mucoadhesive polymer and a bioactive agent such as, but not limited to, an Immunogenic Substance (e.g., a vaccine), that allows the oral or nasal administration and delivery of the bioactive agent essentially unaltered to mucosal surfaces in the animal, including an aquatic animal.

Подробнее
Номер записи: 42
16-02-2012 дата публикации

Brimonidine compositions for treating erythema

Номер: US20120040016A1
Автор: Christopher V. Powala, Klaus P. Theobald
Принадлежит: Individual

The present invention is directed to a pharmaceutical composition including brimonidine tartrate in an amount from about 0.17 percent by weight to about 0.19 percent by weight in a pharmaceutically acceptable carrier such as a gel or cream. The invention also relates to a method of treating erythema in a patient with rosacea by administering the composition of the invention to the site of erythema on the skin of the patient.

Подробнее
Номер записи: 43
16-02-2012 дата публикации

Novel biomaterials, their preparation and use

Номер: US20120040901A1
Автор: Christian Schoch, György Lajos KIS, Jozsef Szejtli, Lajos Szente
Принадлежит: Individual

The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an amphiphilic ammonium-type component, which precipitate is obtainable by a process including the following steps: 1. contacting the anionic polymeric component and an cyclodextrin component in an aqueous medium, and 2. adding to the mixture obtained in step 1 said amphiphilic ammonium-type component, wherein said components are present in amounts effective to form said precipitate, and preferably to corresponding precipitates additionally comprising said cyclodextrin component. Both types of precipitates may optionally comprise one or more further components. The precipitates are particularly useful as controlled-release depot formulations suitable for long-lasting delivery of said further components. The further components incorporated into the precipitates can be pharmaceutical compounds, pesticides, agrochemicals, colorants, diagnostics, enzymes, foodstuffs etc.

Подробнее
Номер записи: 44
16-02-2012 дата публикации

Multiple section parenteral drug delivery apparatus

Номер: US20120041355A1
Автор: Carl F. Edman, Darrel D. Drinan, Robert P. Lackey
Принадлежит: Individual

The invention relates to a parenteral therapeutic agent delivery device. The therapeutic agent delivery device has a disposable section and an implant section suitable for long term implantation within the tissue of a subject. When necessary, the disposable section can be detached from the implant section, and a new disposable section can be attached. The disposable section may contain a reservoir containing the therapeutic agent, a pump for dispensing the therapeutic agent, controlling circuitry for regulating the dispensing of the therapeutic agent, and transceiver circuitry and an antenna for wireless communication with external devices.

Подробнее
Номер записи: 45
16-02-2012 дата публикации

Method of controlled drug release from a liposome carrier

Номер: US20120041357A1
Автор: Daniel Fologea, Greg Salamo, Michael J. Borrelli, Peter M. Corry, Ralph Henry
Принадлежит: University of Arkansas

Disclosed are methods and compositions for the controlled release of a drug or agent from a liposome using light or radiation. Also disclosed are compositions comprising liposomes having a lipid layer, wherein the liposomes contain an agent, an enzyme capable of releasing the agent from the liposome, and an enzyme activator sequestered by a molecular cage. In another aspect, methods of delivering an agent to a target in a subject are disclosed.

Подробнее
Номер записи: 46
16-02-2012 дата публикации

Biologic treatment system and method

Номер: US20120041418A1
Автор: Thomas Q. Dinh
Принадлежит: AMS Research LLC

A delivery system is provided that is adapted to treat various urological pelvic disorders, such as prolapse, incontinence, and the like. The delivery system can include at least one biologic loaded or otherwise provided with a bioactive agent. The biologic can comprise any drugs, hormones or steroids, stem cells, growth factors, proteins, and/or other bioactive agents to promote cell or tissue growth for the treatment and strengthening of organ walls or tissue. The biologic is generally adapted to controllably release the agent to the surrounding tissue or organ to provide a local and targeted delivery.

Подробнее
Номер записи: 47
23-02-2012 дата публикации

Long-Term Storage of Non-Glycosylated Recombinant Human G-CSF

Номер: US20120042613A1
Автор: Helmut Lerch, Klaus Graumann, Thomas Lauber
Принадлежит: SANDOZ AG

The present invention provides a method for stable long-term storage of non-glycosylated recombinant human G-CSF, wherein an aqueous acetate or glutamate buffered G-CSF composition containing non-glycosylated recombinant human G-CSF and sorbitol is cooled to a temperature of −15° C. or below to obtain a frozen G-CSF composition, which frozen composition is then stored in the frozen state. The temperature of the frozen G-CSF composition is later increased to a temperature within the range of from 2° C. to 8° C. for a time selected to allow the G-CSF composition to thaw and to obtain a liquid G-CSF composition having a G-CSF content of at least 95% of the G-CSF content of the original composition.

Подробнее
Номер записи: 48
23-02-2012 дата публикации

Method of stabilizing and sterilizing peptides or proteins

Номер: US20120045431A1
Автор: John T. Trogden, Robert T. Lyons
Принадлежит: Allergan Inc

The present invention provides a method for sterilizing a protein-containing bioerodible implant. The sterilization is accomplished using β-radiation, or high energy electrons. Following sterilization the implant can be used in a variety of methods for the sustained release of a therapeutic protein to treat a disease or condition in a human or non-human subject. The sterilization process is compatible with proteins containing one or more disulfide bonds or easily oxidized methionine residues.

Подробнее
Номер записи: 49
23-02-2012 дата публикации

Stabilized anti-respiratory syncytial virus (rsv) antibody formulations

Номер: US20120045456A1
Автор: Christian B. Allan, Cynthia N. Oliver, Stephen T. Chang
Принадлежит: MEDIMMUNE LLC

The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.

Подробнее
Номер записи: 50
23-02-2012 дата публикации

Thermosensitive hepatitis b vaccine

Номер: US20120045511A1
Автор: Ho-Yuan Chou, Hsin-Hsin Shen, Mi-Hua Tao, Tsai-Yu Lin
Принадлежит: Industrial Technology Research Institute ITRI

A thermosensitive hepatitis B vaccine is provided. The thermosensitive hepatitis B vaccine includes an aqueous phase solution comprising a biodegradable thermosensitive hydrogel copolymer; a surface antigen of hepatitis B virus (HBsAg); and a bioactive substance. The thermosensitive hepatitis B vaccine of the disclosure is particularly suitable for being applied in the patients, which are low responsive or non-responsive to conventional hepatitis B vaccine, for enhancing the induction of cell-mediated immune responses and overcoming the HBsAg non-responsiveness.

Подробнее
Номер записи: 51
23-02-2012 дата публикации

Calcium Formate for Use as a Dietary Supplement

Номер: US20120046252A1
Автор: Hector F. DeLuca
Принадлежит: Individual

A calcium formate composition for oral administration to an individual for the purpose of supplementary dietary calcium is disclosed.

Подробнее
Номер записи: 52
23-02-2012 дата публикации

STABLE PHARMACOLOGICALLY ACTIVE COMPOSITIONS INCLUDING VITAMIN D CONTAINING AND CORTICOSTEROID COMPOUNDS WITH LOW pH COMPATIBILITY

Номер: US20120046253A1
Автор: Michael Fox, Rakefet Cohen
Принадлежит: Teva Pharmaceutical Industries LTD

Provided are pharmaceutical compositions comprising at least one vitamin D-containing compound, at least one corticosteroid compound, and at least one solvent component selected from the group consisting of triglycerides, sorbitan, sorbitan fatty esters, cetearyl glucoside, PEG-n sorbitan stearate, acrylamide/sodium acryloyldimethyl taurate copolymers, and mixtures thereof. Also provided are methods of making such compositions, and methods for treating psoriasis using such compositions.

Подробнее
Номер записи: 53
23-02-2012 дата публикации

Controlled cannabis decarboxylation

Номер: US20120046352A1
Автор: Andrew David Hospodor
Принадлежит: Individual

The invention is a process for the controlled decarboxylation of cannabis wherein Medicinal Delta-9 tetrahydrocannabinol (Δ 9 -THC) and other cannabinoid medicinal substances are decarboxylated through a chemical reaction facilitated by a cofactor. The amount of medicinal cannabis decarboxylated will be directly proportional to the amount of cofactor used. Use a small amount of the cofactor and only some of the medicinal cannabis contained in raw cannabis will be converted from an acidic form into a non-acidic form. Use a large amount of the cofactor and most or all of the medicinal cannabis will be decarboxylated. The reaction is proportional to the molar mass of cofactor.

Подробнее
Номер записи: 54
23-02-2012 дата публикации

Glutathione-based delivery system

Номер: US20120046445A1
Автор: Ae-June Wang, Chi-Heng Jian, Shin-Jr Liu, Shyn-Dar Li, Yi-Fong Lin
Принадлежит: Individual

A delivery system is provided. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative bonded thereto, and a glutathione (GSH) or a glutathione derivative bonded to the polyethylene glycol or the polyethylene glycol derivative.

Подробнее
Номер записи: 55
01-03-2012 дата публикации

Process to form a tablet and apparatus suitable for applying this process

Номер: US20120049412A1
Автор: Hans Almer Middlebeek, Jozefus A.C. Smit
Принадлежит: Intervet International BV

The present invention pertains to a process for the preparation of a fast-disintegrating tablet ( 30 ) containing a medicinal substance, comprising the steps of providing a fluid formulation comprising the medicinal substance, providing a solid element ( 100 ) having formed therein at least one cavity, ( 101 ) cooling the solid element ( 100 ) to a temperature below a freezing temperature of the formulation, filling the cavity with the fluid formulation, solidifying the formulation while present in the cavity ( 101 ) to form a solid pellet comprising the medicinal substance without actively shaping the entire surface of the pellet, taking the pellet out of the cavity and drying the pellet in a vacuum to obtain the tablet. The invention also pertains to a system for performing such a process and a package containing the resulting tablet.

Подробнее
Номер записи: 56
01-03-2012 дата публикации

Peripheral blood sparc binding antibodies and uses thereof

Номер: US20120052007A1
Автор: Neil Desai, Vuong Trieu, Xiping Liu
Принадлежит: Abraxis Bioscience Llc

The invention provides SPARC binding antibodies that have high affinity to SPARC, particularly plasma SPARC, and methods of using such antibodies in treating conditions including cancer.

Подробнее
Номер записи: 57
01-03-2012 дата публикации

Inhibition of undesired sensory effects by the compound camphor

Номер: US20120052021A1
Автор: Diana McKinney, Gerd Kobal, Maria Gogova, Prasad Babu Deenadayalan Polur
Принадлежит: PHILIP MORRIS USA INC

A smokeless tobacco product or medicinal nicotine product includes nicotine and camphor dissolved in a non-flavored oily carrier. Preferably, the camphor is present in a concentration ranging from about 600 ppm to about 1300 ppm. Also disclosed are methods of making such products.

Подробнее
Номер записи: 58
01-03-2012 дата публикации

Immunogenic epitopes of ngep antigen

Номер: US20120052116A1
Автор: Ira Pastan, Jeffrey Schlom, Kwong-Yok Tsang
Принадлежит: US Department of Health and Human Services

The invention provides a peptide comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) New Gene Expressed in Prostate (NGEP), which can be used in vaccine prevention or therapy of prostate cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof.

Подробнее
Номер записи: 59
01-03-2012 дата публикации

Pharmaceutical composition for diabetic nephropathy and its preparation and application

Номер: US20120053236A1
Автор: Bao He, Dan Tang, Fei GU, Huiquan Cheng, Quan Zhu, Rushang Wang, Tingting Duan, Xiaoling Huang, Xinghua Shi, Yanxia Huang, Zhaoguang Zheng
Принадлежит: GUANGZHOU CONSUN MEDICINE R AND D CO Ltd

The invention relates to application of 4,4′-diphenylmethane-bis(methyl) carbamates (DPMC) extracted and isolated from Cortex Mori and preparation of medicine for diabetic nephropathy. The pharmaceutical composition is made up of DPMC as active ingredient and the normal drug carriers, and the weight percentage of active ingredient is 0.1-99.5%. For the remarkable effect of prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients.

Подробнее
Номер записи: 60
08-03-2012 дата публикации

Implantable Punctal Plug

Номер: US20120055490A1
Автор: Casey Jean Lind, Robert Joseph Sanchez, JR.
Принадлежит: Alcon Research LLC

A punctal plug is disclosed, wherein the punctal plug includes a body portion and a retaining portion. The body portion is defined by an open distal end, an open proximal end and a wall portion. The wall portion further includes at least one window extending therethrough. The retaining flange is configured to have an outer periphery that is larger than the outer periphery of the body portion. A method of delivering a therapeutic agent to a patient using a punctal plug is also disclosed.

Подробнее
Номер записи: 61
08-03-2012 дата публикации

Modulation of drug release rate from electrospun fibers

Номер: US20120058100A1
Автор: Jay C. Sy, V. Prasad Shastri
Принадлежит: Individual

Disclosed are co-electrospun polymeric fibers comprising polymers comprising pharmaceutically active agents and/or biologically active agents and capable of release at a combined release rate. Also disclosed are processes for preparing polymeric fibers capable of release at a combined release rate. Also disclosed are processes of modulating delivery rate of pharmaceutically active agents and/or biologically active agents. Also disclosed are processes of delivering pharmaceutically active agents and/or biologically active agents. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Подробнее
Номер записи: 62
08-03-2012 дата публикации

Therapeutic or prophylactic agent for dyskinesia

Номер: US20120058186A1
Автор: Kotoe Ohta, Suguru Takaki, Yasuhide Horiuch
Принадлежит: TORAY INDUSTRIES INC

The present invention relates to a stable orally disintegrating coated tablet containing a drug, wherein the tablet is coated with a coating layer containing a water-soluble substance and a polyvinyl alcohol resin of not less than 5% by weight based on the weight of the coating layer, the water-soluble substance dissolving in an amount of 1 g or more in less than 10 mL of water at 20° C., having a hydroxyl group(s) in its molecule, and having a molecular weight of not more than 200 per a unit hydroxyl group. There is provided a stable orally disintegrating coated tablet which does not cause a crack in the coating layer even when the orally disintegrating tablet has been swollen by moisture absorption under high humidity, while ensuring rapid disintegration properties in an oral cavity. In the case of an orally disintegrating tablet containing a light-unstable drug, degradation of the drug can be suppressed by blending a light shading agent in the coating layer.

Подробнее
Номер записи: 63
08-03-2012 дата публикации

Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin

Номер: US20120058199A1
Автор: Andreas Buthe, Andreas Hafner, Babette Fiedler, Franz Kaufmann, Gordon Bradley, Guido Meurer
Принадлежит: BASF SE

The present invention provides the use of surface active proteins, especially class I and class II hydrophobins, in topically applied pharmaceutical formulations. The invention is particularly directed to topically applied pharmaceutical products for enhancing the penetration to achieve a transungual delivery of a prophylactically and/or therapeutically effective amount of an active ingredient (drug) to a patient (including animals and humans) into and/or through a nail, of the animal or human body, in order to treat one or more of a variety of diseases or disorders. Related embodiments of the invention are also disclosed.

Подробнее
Номер записи: 64
08-03-2012 дата публикации

Purified Plasmodium and Vaccine Compositions

Номер: US20120058543A1
Автор: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
Принадлежит: Sanaria Inc

Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.

Подробнее
Номер записи: 65
08-03-2012 дата публикации

Methods of Treating Neurological Disorders

Номер: US20120058949A1
Автор: Alon Friedman, Daniela Kaufer, Luisa Cacheaux
Принадлежит: Alon Friedman, Daniela Kaufer, Luisa Cacheaux

The present invention provides methods of treating epilepsy and other neurological disorders. The methods generally involve administering to an individual in need thereof an effective amount of an agent that blocks a transforming growth factor-beta pathway.

Подробнее
Номер записи: 66
08-03-2012 дата публикации

Phosphonate Compounds

Номер: US20120058975A1
Автор: Ganesh D. Kini, James R. Beadle, Karl Y. Hostetler
Принадлежит: UNIVERSITY OF CALIFORNIA

The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.

Подробнее
Номер записи: 67
08-03-2012 дата публикации

Combinations comprising antimuscarinic agents and pde4 inhibitors

Номер: US20120059031A1
Автор: Hamish Ryder, Jesus Llenas Calvo, Jordi Gras Escardo, Pio Orviz Diaz
Принадлежит: Individual

A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.

Подробнее
Номер записи: 68
08-03-2012 дата публикации

Method for reducing thrombocytopenia and thrombocytopenia-associated mortality

Номер: US20120059036A1
Автор: Marco Valgimigli
Принадлежит: Individual

Disclosed are methods for reducing the risk of thrombocytopenia-associated mortality and morbidity, and for reducing the risk of becoming thrombocytopenic, in patients whose treatment requires inhibition of platelet aggregation. The methods involve administration of a pharmaceutically acceptable salt of tirofiban.

Подробнее
Номер записи: 69
08-03-2012 дата публикации

Antiviral treatments

Номер: US20120059057A1
Автор: John Michael Kilpatrick, Pooran Chand, Shane Arnold, Shanta Bantia, Yarlagadda Sudhakara Babu
Принадлежит: BioCryst Pharmaceuticals Inc

The invention provides unit dosage forms, kits, and methods useful for treating viral infections.

Подробнее
Номер записи: 70
08-03-2012 дата публикации

Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor

Номер: US20120059462A1
Автор: Vernon G. Wong
Принадлежит: Allergan Inc

Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.

Подробнее
Номер записи: 71
15-03-2012 дата публикации

Delivery system with scaffolds

Номер: US20120063997A1
Автор: Cheryl Hunter, Kevin Morris Shakessheff, Robin Andrew Quirk
Принадлежит: REGENTEC Ltd

An injectable, agent delivery system comprising a composition comprising: (i) an injectable scaffold material comprising discrete particles, which are capable of interacting to form a scaffold; and (ii) a carrier comprising an agent for delivery. The product can have a pharmaceutical use or use in cosmetic surgery; in particular it can be used in tissue regeneration or reconstruction. The agent for delivery may be a therapeutically, prophylactically or diagnostically active substance.

Подробнее
Номер записи: 72
15-03-2012 дата публикации

Preparation for external application

Номер: US20120064011A1
Автор: Dirk Schumann
Принадлежит: Bubbles and Beyond GmBH

Preparations for external application to human and animal skin, comprising: a) a composition in the form of a fluid nanophase system, comprising the components of a1) at least one water-insoluble substance with a water solubility of less than 4 gram per liter, a2) at least one amphiphilic substance (NP-MCA), which has no surfactant structure, does not build structures alone, the solubility of which is between 4 g and 1000 g per liter in water or oil and which does not enrich preferably at the oil-water interface, a3) at least one anionic, cationic, amphoteric and/or non-ionic surfactant, a4) at least one polar protic solvent, in particular having hydroxy functionality, a5) if necessary one or more adjuvants, wherein the percentage relate to the total weight of the composition each; and b) a therapeutic, cosmetic or diagnostically effective agent in a therapeutic, cosmetic or diagnostically effective amount.

Подробнее
Номер записи: 73
15-03-2012 дата публикации

Azeotrope-like compositions comprising 1-chloro-3,3,3-trifluoropropene

Номер: US20120064014A1
Автор: David J. Williams, Gary Knopeck, Hang T. Pham, Kane Cook, Leslie Bement, Rajat Basu, Rajiv R. Singh, Ryan Hulse
Принадлежит: Honeywell International Inc

An azeotrope-like mixture consisting essentially of chlorotrifluoropropene and at least one component selected from the group consisting of a C 1 -C 3 alcohol, a C 5 -C 6 hydrocarbon, a halogenated hydrocarbon, methylal, methyl acetone, water, nitromethane, and combinations thereof.

Подробнее
Номер записи: 74
15-03-2012 дата публикации

Treatment of cancer

Номер: US20120064071A1
Автор: John Ryan
Принадлежит: Cerulean Pharma Inc

Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.

Подробнее
Номер записи: 75
15-03-2012 дата публикации

Biocompatible materials containing stable complexes of tsg-6 and hyaluronan and method of using same

Номер: US20120064150A1
Автор: Hans-Georg Wisniewski, Mary K. COWMAN, Philip Band
Принадлежит: Polytechnic Institute of NYU

The present invention provides a biocompatible material in the form of a solid, a water insoluble cross-linked gel or a liposome, which contains a stable comples of TNF-stimulated gene 6 protein (TSG-6) and hyaluronan.

Подробнее
Номер записи: 76
15-03-2012 дата публикации

Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs

Номер: US20120064156A1
Автор: John R. Plachetka
Принадлежит: Individual

The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.

Подробнее
Номер записи: 77
15-03-2012 дата публикации

Stabilized biodegradable neurotoxin implants

Номер: US20120065141A1
Автор: Orest Olejnik, Patrick M. Hughes
Принадлежит: Allergan Inc

Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer. The implants disclosed herein may be administered to a human or animal patient in which a therapeutic effect is desired for prolonged periods of time.

Подробнее
Номер записи: 78
15-03-2012 дата публикации

Delivery system for delivery of a substance into the oral cavity

Номер: US20120065160A1
Автор: Jonatan Moses
Принадлежит: NEOINVENT MEDICAL ENGR AB

A delivery system for use in the oral cavity, the system comprising a carrier for a bioactive substance. The carrier has a surface comprising oxygen-binding sites (X), and at least one link comprising a pentose group and one or more additional sugar groups, the pentose group being bonded to one of said oxygen binding sites (X) and wherein one or more bioactive molecules (R) are bonded directly to one of the sugar groups of the at least one link or to one or more substituents on one or more sugar groups in the at least one link.

Подробнее
Номер записи: 79
22-03-2012 дата публикации

Low-Density Magnesium-Aluminum-Silicate (MAS) Microparticles for Radiotherapy and/or Radioimaging

Номер: US20120070371A1
Автор: Delbert E. Day, Yiyong He
Принадлежит: Individual

This invention relates to low density radioactive magnesium-aluminum-silicate (MAS) microparticles that contain either samarium-yttrium, samarium, or lutetium as medical isotopes for radiotherapy and/or radioimaging.

Подробнее
Номер записи: 80
22-03-2012 дата публикации

Oral composition and method of forming and using same

Номер: US20120070423A1
Автор: Puneet Nanda
Принадлежит: Dr Fresh LLC

An oral composition for the treatment of dry mouth symptoms and other conditions, a method of forming the oral composition, and a method of using the oral composition are disclosed. The oral composition includes a plurality of enzymes to prevent formation of and/or facilitate the break up of biofilm in an oral cavity and a metal ion management system to inhibit growth of gram negative bacteria.

Подробнее
Номер записи: 81
22-03-2012 дата публикации

Flavonoid hydrogel

Номер: US20120070433A1
Автор: Fan Lee, Joo Eun Chung, Motoichi Kurisawa, Pui Yik Chan
Принадлежит: Agency for Science Technology and Research Singapore

There is provided methods for producing a hydrogel comprising conjugates of a hydrogel forming agent and a flavonoid including a method for producing a hydrogel that is capable of adhesion of cells and which comprises enzymatically cross-linked conjugates of a hydrogel forming agent and a flavonoid. There is also provided a method for producing a hydrogel comprising conjugates of a hydrogel forming agent and a flavonoid without the addition of an exogenous peroxide or peroxidase or without the addition of an exogenous peroxide. Hydrogels produced by such methods and methods of using the hydrogels are also described herein.

Подробнее
Номер записи: 82
22-03-2012 дата публикации

Novel solid forms of bendamustine hydrochloride

Номер: US20120071532A1
Автор: Laurent D. Courvoisier, Mark Eddleston, Martin Ian Cooper, Robert E. Mckean
Принадлежит: Cephalon Inc

Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.

Подробнее
Номер записи: 83
29-03-2012 дата публикации

STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph

Номер: US20120076779A1
Автор: Christa Mayer, Hans-Peter Schwarz, Harald Arno Butterweck, Lucia Hofbauer, Meinhard Hasslacher, Oliver Zoechling, Theresa Friederike Bauer, Wolfgang Teschner
Принадлежит: Baxter Healthcare SA, Baxter International Inc

The present invention provides, among other aspects, storage stabile aqueous formulations of labile proteins at a mildly acidic to neutral pH. The present invention also provides methods for stabilizing a labile therapeutic protein composition at a mildly acidic to neutral pH. Advantageously, the methods and formulations provided herein allow stabile aqueous compositions of labile proteins at mildly acidic to neutral pH useful for parenteral administration.

Подробнее
Номер записи: 84
29-03-2012 дата публикации

Drug carrier and drug carrier kit for inhibiting fibrosis

Номер: US20120076852A1
Автор: Junji Kato, Yasushi Sato, Yoshiro Niitsu
Принадлежит: Nitto Denko Corp

An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

Подробнее
Номер записи: 85
29-03-2012 дата публикации

Materials and Methods for the Treatment of Pathological Neovascularization in the Eye

Номер: US20120077870A1
Автор: C. Kathleen DOREY, Howard M. Prentice, Janet C. BLANKS
Принадлежит: Blanks Janet C, Dorey C Kathleen, Prentice Howard M

The subject invention provides materials and methods useful in safely and effectively preventing pathological proliferation of blood vessels. The prevention of the over-proliferation of blood vessels according to the subject invention is particularly advantageous for treatment of certain ocular conditions including age-related macular degeneration (AMD), retinopathy of prematurity (ROP) and diabetic retinopathy. In preferred embodiments, the subject invention provides materials and methods for effective treatment of pathological ocular neovascularization using gene therapy. In a specific embodiment the materials and methods of the subject invention can be used to treat AMD.

Подробнее
Номер записи: 86
29-03-2012 дата публикации

Remotely imageable marker system and polysaccharide marker for use in same

Номер: US20120078092A1
Автор: Michael L. Jones, Paul Lubock
Принадлежит: SenoRx Inc

A remotely imageable marker system includes a tubular delivery member having an inner lumen and a plurality of marker members. Each marker member of the plurality of marker members comprises a bioabsorbable polysaccharide in sufficient amount to exhibit hemostatic properties and a binder. The plurality of marker members is disposed within the inner lumen of the tubular delivery member.

Подробнее
Номер записи: 87
05-04-2012 дата публикации

Easily administrable solid preparation

Номер: US20120082723A1
Автор: Kuniomi Warabino, Yumio Kudou
Принадлежит: Mochida Pharmaceutical Co Ltd

It is an object to provide a coating composition, which is used for an orally-administered preparation, the administering property of which has been improved, and/or an easily administrable preparation that does not affect dissolution property. The aforementioned object can be achieved using a coating composition comprising a first thickener selected from the group consisting of a carboxyvinyl polymer and sodium alginate, a polyvalent metal compound, and at least one type of a second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate, with the proviso that when the first thickener is sodium alginate the second thickener is not sodium alginate, or using a coating composition comprising, as thickeners, hydroxypropylmethylcellulose and sugar or sugar alcohol having a solubility at 20° C. of 30 or more.

Подробнее
Номер записи: 88
05-04-2012 дата публикации

Novel albumin-free factor viii formulations

Номер: US20120083446A1
Автор: Erik Bjornson, Feroz Jameel, John Carpenter, Marc Besman, Michael Pikal, Ramesh Kashi, Serguei Tchessalov
Принадлежит: Baxter International Inc, University of Connecticut

An albumin-free Factor VIII formulation comprising, 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent.

Подробнее
Номер записи: 89
05-04-2012 дата публикации

Topical Anesthetic Uses of Szeto-Schiller Peptides

Номер: US20120083452A1
Автор: Nicholas V. Perricone
Принадлежит: Individual

Topical anesthetic compositions include Szeto-Schiller peptides and a dermatologically acceptable carrier, and optionally a vasoconstrictor and tyrosine. A method of providing local analgesia to the skin involves applying to skin the topical anesthetic compositions.

Подробнее
Номер записи: 90
05-04-2012 дата публикации

Method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis

Номер: US20120083468A1
Автор: Anders Wieslander, Ola Carlsson, Tobjörn Linden
Принадлежит: Individual

A method of preparing a medical solution includes the steps of a) providing a solution having one or more acetylated or deacetylated amino sugar/sugars in at least one compartment of a container at a pH of from 2.5 to 5.0, and b) terminal sterilization of the compartment and the contents therein. The solution can be used for manufacturing a medicament for peritoneal dialysis.

Подробнее
Номер записи: 91
12-04-2012 дата публикации

Nasal spray device

Номер: US20120085345A1
Автор: Armando Morales, Declan Walsh, Jade Ching-Ying Ly, Xian-Ming Zeng
Принадлежит: Norton Waterford Ltd, Teva Branded Pharmaceutical Products R&D Inc

A nasal spray device for the delivery of a pharmaceutical formulation to the nasal cavity in metered doses. The device includes: a pressurised aerosol canister including a vial containing a pharmaceutical formulation including an active ingredient, a propellant and, optionally, a co-solvent, the aerosol canister further including a metering valve having a valve stem; and an actuator for the aerosol canister, the actuator including a stem block having a receptacle into which the valve stem of metering valve of the aerosol canister is received and axially located and being displaceable relative to the vial of the aerosol canister to actuate the metering valve of the aerosol canister, a sump extending below the receptacle, the stem block further defining a discharge orifice for the pharmaceutical formulation and a transfer channel through which a dispensed dose of the pharmaceutical formulation is able to pass from the sump to the discharge orifice.

Подробнее
Номер записи: 92
12-04-2012 дата публикации

Use of inhibitors of bruton's tyrosine kinase (btk)

Номер: US20120087915A1
Автор: David J. Loury, Eric Hedrick, Gwen Fyfe, Joseph J. Buggy, Laurence Elias, Tarak D. Mody
Принадлежит: Pharmacyclics LLC

Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

Подробнее
Номер записи: 93
12-04-2012 дата публикации

Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical fromulations

Номер: US20120088726A1
Автор: Annalisa Sforzini, Carla Caramella, Giuseppe Bottoni, Giuseppe Claudio Viscomi, Mascia Federici, Paola Maffei, Silvia Rossi
Принадлежит: Alfa Wasserman SpA

Object of the invention are mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients.

Подробнее
Номер записи: 94
12-04-2012 дата публикации

Compositions for treating cmt and related disorders

Номер: US20120088744A1
Автор: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin
Принадлежит: Pharnext SA

The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.

Подробнее
Номер записи: 95
12-04-2012 дата публикации

Chemically modified small molecules

Номер: US20120088745A1
Автор: C. Simone Fishburn, Chester Leach, David Lechuga-Ballesteros, Hema Gursahani, Mei-chang Kuo, Tacey Viegas, Yuan Song
Принадлежит: Individual

Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.

Подробнее
Номер записи: 96
12-04-2012 дата публикации

Implantable Drug Delivery Device with Bladder Retention Feature

Номер: US20120089121A1
Автор: Heejin Lee, Hong Linh Ho Duc
Принадлежит: Taris Biomedical Inc

Implantable devices and methods for controlled drug delivery are provided. The device includes a device structure deformable between a retention shape and a low profile shape for deployment in the bladder of a patient and has a drug reservoir lumen in which a drug formulation is housed. The device also includes a buoyancy retention portion, which includes a volume of entrapped air or a gas-generating or effervescent powder Which will generate a volume of entrapped air following contact with urine in the bladder. The buoyancy retention portion may include a water permeable and/or biodegradable wall, which can release the entrapped air following drug release, to cause the device to sink into the bladder neck to facilitate device expulsion without the need for a device retrieval medical procedure.

Подробнее
Номер записи: 97
19-04-2012 дата публикации

Flameless electronic atomizing cigarette

Номер: US20120090630A1
Автор: LIK Hon
Принадлежит: Individual

A non-smokable electronic spray cigarette which provides nicotine without harmful tar. The cigarette may include a mouthpiece, a high frequency ionizer, nicotine solution storage and its container, control circuit, and a high temperature vaporization nozzle and attachments. The advantages of the present invention are smoking without tar, reducing the carcinogenic risk, the user still experiencing the pleasure of smoking and no fire danger.

Подробнее
Номер записи: 98
19-04-2012 дата публикации

Sustained-release formulation for injection

Номер: US20120091022A1
Автор: Norimasa Koseki, Takashi Nakagawa
Принадлежит: Sumitomo Dainippon Pharma Co Ltd

The present invention relates to a composition comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof. In detail, the composition relates to a sustained release formulation for injection which maintains an effective blood level of the above-mentioned compound.

Подробнее
Номер записи: 99
19-04-2012 дата публикации

Peptide fragments for inducing synthesis of extracellular matrix proteins

Номер: US20120093740A1
Автор: Lijuan Zhang, Scott M. Harris, Timothy J. Falla
Принадлежит: Helix Biomedix Inc

Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.

Подробнее
Номер записи: 100